Spyre Therapeutics (SYRE) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$16.8 million.
- Spyre Therapeutics' Net Cash Flow fell 16422.47% to -$16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year increase of 6723.18%. This contributed to the annual value of -$99.8 million for FY2024, which is 16531.81% down from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Net Cash Flow is -$16.8 million, which was down 16422.47% from $33.2 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Net Cash Flow ranged from a high of $200.1 million in Q2 2023 and a low of -$182.4 million during Q2 2024
- In the last 5 years, Spyre Therapeutics' Net Cash Flow had a median value of -$492000.0 in 2022 and averaged -$1.4 million.
- Per our database at Business Quant, Spyre Therapeutics' Net Cash Flow tumbled by 1122674.87% in 2023 and then skyrocketed by 3058253.97% in 2024.
- Quarter analysis of 5 years shows Spyre Therapeutics' Net Cash Flow stood at -$9.5 million in 2021, then skyrocketed by 56.45% to -$4.1 million in 2022, then soared by 2445.66% to $97.3 million in 2023, then tumbled by 81.65% to $17.9 million in 2024, then tumbled by 193.86% to -$16.8 million in 2025.
- Its last three reported values are -$16.8 million in Q3 2025, $33.2 million for Q2 2025, and -$40.9 million during Q1 2025.